Results 121 to 130 of about 14,184,553 (374)

Chemical Chaperones Improve Protein Secretion and Rescue Mutant Factor VIII in Mice with Hemophilia A. [PDF]

, 2012
nefficient intracellular protein trafficking is a critical issue in the pathogenesis of a variety of diseases and in recombinant protein production.
Abriss, Daniela, Milanov, Peter, Pepperkok, Rainer, Quade-Lyssy, Patricia, Roth, Stefanie D., Schüttrumpf, Jörg, Seifried, Erhard, Simpson, Jeremy C., Tonn, Torsten, Ungerer, Christopher   +9 more
core   +2 more sources

Activated clotting factors in factor IX concentrates [PDF]

Blood, 1979
The precise quantitation of activated factors in human factor IX concentrates has been accomplished with the use of recently developed, specific assays for factors IXa, Xa, and thrombin. The assay for factor IXa, which measures the initial rate of 3H-factor-X activation, was shown to be specific for factor IXa in the concentrates.
openaire   +4 more sources

KMT2A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells

Molecular Oncology, Volume 19, Issue 5, Page 1404-1421, May 2025.
We demonstrate that decitabine (DEC) not only degrades the DNA methyltransferase DNMT1 but also the leukemic driver lysine methyltransferase KMT2A likely due to structural similarity of the DNA‐binding CXXC domains. DEC influences KMT2A downstream processes and synergizes with menin inhibitor revumenib (REV) to decrease leukemic cell proliferation, and
Luisa Brock, Lina Benzien, Sandra Lange, Maja Huehns, Alexandra Runge, Catrin Roolf, Anett Sekora, Gudrun Knuebel, Hugo Murua Escobar, Christian Junghanss, Anna Richter   +10 more
wiley   +1 more source

A Sequential Mechanism for Exosite-mediated Factor IX Activation by Factor XIa*

Journal of Biological Chemistry, 2012
Background: Factor XIa proteolytically activates factor IX. Results: XIa cleaves IX after Arg145, forming IXα, and then after Arg180, forming IXaβ. Both reactions require substrate binding to the XIa A3 domain.
Yipeng Geng, I. Verhamme, A. Messer, Mao-fu Sun, Stephen B. Smith, S. Bajaj, D. Gailani   +6 more
semanticscholar   +1 more source

A study to determine the prevalence, clinical profile and incidence of formation of inhibitors in patients of hemophilia in north eastern part of India

Journal of Family Medicine and Primary Care, 2019
Introduction: Deficiency of factor VIII (Hemophilia A), factor IX (Hemophilia B) and Von Willebrand's factor are the most frequent coagulation defects.
Sandip Kumar, Sachidanand Sinha, Anju Bharti, Lalit P Meena, Vineeta Gupta, Jyoti Shukla   +5 more
doaj   +1 more source

CRISPR targeting of FOXL2 c.402C>G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti‐tumoral compounds

Molecular Oncology, Volume 19, Issue 4, Page 1092-1116, April 2025.
FOXL2 c.402C>G mutation drives granulosa cell tumors. Using CRISPR technology, we selectively corrected this mutation, reducing malignancy and increasing sensitivity to dasatinib and ketoconazole. Transcriptomic changes revealed potential therapeutic targets, demonstrating CRISPR's promise for treating this rare ovarian cancer.
Sandra Amarilla‐Quintana, Paloma Navarro, Iván Hernández, Alejandra Ramos, Ana Montero‐Calle, Pablo Cabezas‐Sainz, Maria J Barrero, Diego Megías, Borja Vilaplana‐Martí, Carolina Epifano, Déborah Gómez‐Dominguez, Sara Monzón, Isabel Cuesta, Laura Sánchez, Rodrigo Barderas, Jesús García‐Donas, Alberto Martín, Ignacio Pérez de Castro   +17 more
wiley   +1 more source

AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

Blood, 2003
Hemophilia B is an X-linked coagulopathy caused by absence of functional coagulation factor IX (F.IX). Previously, we established an experimental basis for gene transfer as a method of treating the disease in mice and hemophilic dogs through ...
C. Manno, A. Chew, S. Hutchison, P. Larson, R. Herzog, V. Arruda, S. J. Tai, M. Ragni, A. Thompson, M. Ozelo, L. Couto, D. Leonard, F. Johnson, A. Mcclelland, C. Scallan, E. Skarsgard, A. Flake, M. Kay, K. High, B. Glader   +19 more
semanticscholar   +1 more source

Clinical significance of stratifying prostate cancer patients through specific circulating genes

Molecular Oncology, Volume 19, Issue 5, Page 1310-1331, May 2025.
We tested a specific panel of genes representative of luminal, neuroendocrine and stem‐like cells in the blood of prostate cancer patients, showing predictive value from diagnosis to late stages of disease. This approach allows monitoring of treatment responses and outcomes at specific time points in trajectories.
Seta Derderian, Edouard Jarry, Arynne Santos, Quentin Vesval, Lucie Hamel, Rafael Sanchez‐Salas, Alexis Rompré‐Brodeur, Wassim Kassouf, Raghu Rajan, Fadi Brimo, Marie Duclos, Armen Aprikian, Simone Chevalier   +12 more
wiley   +1 more source

Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk? [PDF]

, 2003
BACKGROUND Conventional hormone replacement therapy (HRT) containing conjugated equine oestrogen (CEE) and medroxyprogesterone acetate (MPA) increases triglyceride, C- reactive protein (CRP) and coagulation Factor VII concentrations, potentially ...
Alan J. Jaap, Andersen, Anderson, Ann Rumley, Anne Kelly, Brussard, Cushman, Dichtl, Ferrara, Gordon D. Lowe, Gornstein, Herrington, Hokanson, Hulley, Ian A. Greer, John R. Petrie, Joyce McKenzie, Kanaya, Kenneth Paterson, Knopp, Koh, Kroon, Kroon, Lokkegaard, Lowe, Lowe, Lowe, Lynne Crawford, Manning, Meade, Naveed Sattar, Perera, Petitti, Pradhan, Rapp, Ridker, Ridker, Rossouw, Sattar, Sattar, Stephen Gallacher, Stork, Van Baal, Van Baal, Vehkavaara, Woodward, Zanger   +46 more
core   +1 more source

Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti‐CD73/anti‐PD‐L1 immunotherapy in arm A of the NSGO‐OV‐UMB1/ENGOT‐OV30 trial

Molecular Oncology, Volume 19, Issue 5, Page 1436-1451, May 2025.
Using mass cytometry, we analyzed serial blood samples from patients with relapsed epithelial ovarian cancer (EOC) treated with oleclumab–durvalumab combination immunotherapy in the NSGO‐OV‐UMB1/ENGOT‐OV30 trial. Our analysis identified potential predictive, monitoring, and response biomarkers detectable through liquid biopsy. These findings facilitate
Luka Tandaric, Annika Auranen, Katrin Kleinmanns, René DePont Christensen, Liv Cecilie Vestrheim Thomsen, Cara Ellen Wogsland, Emmet McCormack, Johanna Mäenpää, Kristine Madsen, Karen Stampe Petersson, Mansoor Raza Mirza, Line Bjørge   +11 more
wiley   +1 more source